VISCHER advised Anaveon on the deal. Anaveon AG, a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110m Series B financing led by incoming investor...
You must be a Standard 1 Year member to access this content.
VISCHER AG advises Polyphor AG on the deal. Walder Wyss advises Enbiotix Inc. on this transaction. Polyphor (SIX: POLN) and EnBiotix Inc., a privately held late...
You must be a Standard 1 Year member to access this content.
VISCHER advised Combioxin SA on the deal. Combioxin SA, a clinical-stage biotechnology company based in Epalinges, Switzerland, entered into a worldwide licensing agreement with Eagle Pharmaceuticals,...
You must be a Standard 1 Year member to access this content.
VISCHER AG has advised Novartis AG in this transaction. Novartis has signed a collaboration agreement and an option to acquire Cellerys. The Zurich-based startup is researching...
You must be a Standard 1 Year member to access this content.
VISCHER advised Haya Therapeutics SA on all legal issues related to the financing round. HAYA Therapeutics SA, a company developing precision medicines that target tissue and...
You must be a Standard 1 Year member to access this content.
VISCHER advised Haya Therapeutics SA on all legal issues related to the financing round. HAYA Therapeutics SA, a company developing precision medicines that target tissue and...
You must be a Standard 1 Year member to access this content.
